IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
Company/Organization Date Area of
Collaboration
ARIUS Research 2006 FunctionFIRST
technology platform
Paradigm Therapeutics
(UK)
2005 Drug discovery (CNS
disorders)
Terms of Agreement
ARIUS Research signed a three-year
collaborative agreement with Takeda to
discover treatments for human disease
using ARIUS’s FunctionFIRST technology
platform. Under the terms of agreement
Takeda will pay an upfront technology
access fee of $2 million ($1 million each in
cash and equity investment, respectively)
as well as research funding for three
years. Confirmed ongoing by Takeda in
2008.
3-year deal to access novel proprietary
therapeutic targets identified by Paradigm
for selected CNS disorders. Takeda will
pay up-front fees and milestones totaling
up to $18m for each product and then
sales royalties.
Flamel Technologies 2004 New formulations TAP licensed the worldwide rights for
Flamel’s Micropump controlled-release
technology for the oral administration of
lansoprazole. TAP will pay costs of further
development, testing, regulatory approval,
and marketing of the new formulation.
HTG 2004 New drug candidates HTG will use its multiplexed ArrayPlate
technology to screen samples provided by
Takeda and gather critical information on
the interplay of genes in biological
systems. HTG will deliver high-quality,
multiplexed gene expression test results to
assist Takeda to identify promising new
drug candidates. Financial terms were not
disclosed. In 2006 Array BioPharma
advanced two lead compounds into
preclinical studies, triggering milestone
payments from Takeda.
© 2009 IMS Health In cor po rated or its af fil i ates Page 101